Back to top
more

Compugen (CGEN)

(Delayed Data from NSDQ)

$1.75 USD

1.75
194,458

+0.12 (7.36%)

Updated Aug 8, 2024 04:00 PM ET

After-Market: $1.75 0.00 (0.00%) 6:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Compugen (CGEN) a New Strong Buy Stock

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Top Ranked Momentum Stocks to Buy for April 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.

Company News for Mar 10, 2020

Companies In The News Are: COCP, CGEN, AAPL, NINE

Ekta Bagri headshot

5 Biotech Stocks That Have More Than Doubled This Year

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

Indrajit Bandyopadhyay headshot

5 Biotech Stocks Up More Than 100% This Year So Far

The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Compugen (CGEN) Upgraded to Buy: Here's What You Should Know

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MyoKardia Begins Dosing in Phase I Study on Heart Candidate

MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.

Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study

Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.

Mallinckrodt Enrolls First Patient in Liver Disease Study

Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Compugen (CGEN) Upgraded to Buy: Here's What You Should Know

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Compugen (CGEN) a New Strong Buy Stock

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4

Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.

Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4

Merrimack's (MACK) loss betters estimates in Q4. However, the company fails to earn any revenues in the period.

Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer

Bristol-Myers (BMY) signs a contract with Infinity Pharmaceuticals to evaluate the combination of its Pd-1 inhibitor Opdivo and Infinity's IPI-549 for treating advanced urothelial cancer

Compugen (CGEN) Reports Q3 Loss

Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.

What Lies in Store for Ligand (LGND) This Earnings Season?

Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.

What's in the Cards for Nektar (NKTR) This Earnings Season?

Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.

Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?

Compugen has been struggling lately, but the selling pressure may be coming to an end soon.